HIV psychiatry

Also known as HIV-associated neurocognitive disorders · HAND · AIDS psychiatry · Neuropsychiatry of HIV · Depression in HIV · ART neuropsychiatric effects

Exam-exhaustive fellowship topic on HIV psychiatry for consultation-liaison practice — Frascati HAND spectrum (ANI/MND/HAD), depression and adherence (CBT-AD, measurement-based care), ART neuropsychiatry (efavirenz, INSTIs), psychotropic–antiretroviral interactions with boosters, stigma and suicide risk, and decision-specific capacity. FRANZCP-primary, globally tagged.

high25 referencesUpdated 26 July 202611 min readVerification in progress

Practise this topic

10 MCQs

Meet the patient

A 52-year-old man, HIV diagnosed sixteen years ago, viral load undetectable for a decade. He is missing appointments. His partner says he pays the same bill twice, loses the thread of conversations, and has stopped cooking. He scores 24 on a MoCA and says, flatly, that none of it matters much any more.^[1]^[4]^[6]

Three diagnoses fit that paragraph and the examiner wants all three named: HAND, depression, and the possibility that his regimen changed six weeks ago. Getting one and stopping is how candidates lose the station.^[1]^[6]^[17]

References25Show

[1]Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders Neurology, 2007.PMID 17914061
[2]Heaton RK, Clifford DB, Franklin DR Jr, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study Neurology, 2010.PMID 21135382
[3]Heaton RK, Franklin DR, Ellis RJ, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors J Neurovirol, 2011.PMID 21174240
[4]Clifford DB, Ances BM HIV-associated neurocognitive disorder Lancet Infect Dis, 2013.PMID 24156898
[5]Letendre S Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder Top Antivir Med, 2011.PMID 22156215
[6]Ciesla JA, Roberts JE Meta-analysis of the relationship between HIV infection and risk for depressive disorders Am J Psychiatry, 2001.PMID 11329393
[7]Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States Arch Gen Psychiatry, 2001.PMID 11483137
[8]Gonzalez JS, Batchelder AW, Psaros C, et al. Depression and HIV/AIDS treatment nonadherence: a review and meta-analysis J Acquir Immune Defic Syndr, 2011.PMID 21857529
[9]Uthman OA, Magidson JF, Safren SA, et al. Depression and adherence to antiretroviral therapy in low-, middle- and high-income countries: a systematic review and meta-analysis Curr HIV/AIDS Rep, 2014.PMID 25038748
[10]Rabkin JG, Wagner GJ, Rabkin R Fluoxetine treatment for depression in patients with HIV and AIDS: a randomized, placebo-controlled trial Am J Psychiatry, 1999.PMID 9892304
[11]Pence BW, Gaynes BN, Adams JL, et al. The effect of antidepressant treatment on HIV and depression outcomes: results from a randomized trial AIDS, 2015.PMID 26134881
[12]Pence BW, Gaynes BN, Williams Q, et al. Assessing the effect of Measurement-Based Care depression treatment on HIV medication adherence and health outcomes: rationale and design of the SLAM DUNC Study Contemp Clin Trials, 2012.PMID 22542960
[13]Safren SA, O'Cleirigh C, Tan JY, et al. A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected individuals Health Psychol, 2009.PMID 19210012
[14]Safren SA, O'Cleirigh CM, Bullis JR, et al. Cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected injection drug users: a randomized controlled trial J Consult Clin Psychol, 2012.PMID 22545737
[15]Kenedi CA, Goforth HW A systematic review of the psychiatric side-effects of efavirenz AIDS Behav, 2011.PMID 21484283
[16]Mollan KR, Tierney C, Hellwege JN, et al. Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants J Infect Dis, 2017.PMID 28931220
[17]Hoffmann C, Llibre JM Neuropsychiatric Adverse Events with Dolutegravir and Other Integrase Strand Transfer Inhibitors AIDS Rev, 2019.PMID 30899113
[18]Goodlet KJ, Zmarlicka MT, Peckham AM Drug-drug interactions and clinical considerations with co-administration of antiretrovirals and psychotropic drugs CNS Spectr, 2019.PMID 30295215
[19]Thompson A, Silverman B, Dzeng L, et al. Psychotropic medications and HIV Clin Infect Dis, 2006.PMID 16586391
[20]Watkins CC, Pieper AA, Treisman GJ Safety considerations in drug treatment of depression in HIV-positive patients: an updated review Drug Saf, 2011.PMID 21751824
[21]Rueda S, Mitra S, Chen S, et al. Examining the associations between HIV-related stigma and health outcomes in people living with HIV/AIDS: a series of meta-analyses BMJ Open, 2016.PMID 27412106
[22]Smith A, Breazeale S, Goulet JL, et al. A Systematic Review of Risk Factors for Suicide Among Persons Living with HIV (1996-2020) AIDS Behav, 2022.PMID 35107660
[23]Appelbaum PS Clinical practice. Assessment of patients' competence to consent to treatment N Engl J Med, 2007.PMID 17978292
[24]Moser DJ, Schultz SK, Arndt S, et al. Capacity to provide informed consent for participation in schizophrenia and HIV research Am J Psychiatry, 2002.PMID 12091200
[25]O'Donnell JK, Gaynes BN, Cole SR, et al. Ongoing life stressors and suicidal ideation among HIV-infected adults with depression J Affect Disord, 2016.PMID 26544615